Table 5.
Summary of Recent Studies Using NLR as a Preoperative Diagnostic Marker
| Author (Year) | Type of Malignancy | Number of Subjects | Measurement | NLR Cut-off value | Comment |
|---|---|---|---|---|---|
| Non-Gynecologic | |||||
| Zheng et al (2018) |
Glioma | 750 | NLR, LMR | 2.25 | Glioma vs acoustic neuroma, menigioma |
| Çolak et al (2019) |
Hodgkin lymphoma | 26 | NLR | 5.8 | Hodgkin lymphoma vs reactive lymphadenopathy |
| Adhyatma et al (2019) |
Prostate cancer | 172 | NLR, PLR, PSA | 3.08 | Prostate cancer vs BPH |
| Yapar et al (2020) |
Enchondroma and low-grade chondrosarcoma. | 101 | NLR, MLR | 2.0 | Cartilaginous tumors vs healthy control |
| Tezol et al (2020) |
Lymphoma in children | 190 | NLR, MLR, PLR, and RDW | 3.17 | Lymphoma vs reactive lymphadenopathy |
| Gynecologic | |||||
| Eo et al (2018) |
EOC | 229 | NLR, LMR, PLR | 2.64 | Malignancy vs benign ovarian mass |
| Kim et al (2010) |
Uterine sarcoma | 34 | NLR, CA-125 | 2.12 | Uterine sarcoma vs leiomyoma |
| Cho et al (2016) |
Uterine sarcoma | 31 | NLR | 2.1 | Uterine sarcoma vs leiomyoma |
| Zhang et al (2020) |
LMS | 45 | NLR, LDH, PLT | 2.8 | Uterine leiomyosarcoma vs leiomyoma |
| Present study | LMS | 79 | NLR, CRP, LDH or combination | 2.157 | Uterine leiomyosarcoma vs leiomyoma |
Abbreviations: EOC, epithelial ovarian cancer; NLR, neutrophil to lymphocyte ratio; MLR, monocyte to lymphocyte ratio; PLR, platelet to lymphocyte ratio; RDW, red cell distribution width; PSA, prostate-specific antigen; CRP, C-reactive protein; LDH, lactate dehydrogenase; LMS, leiomyosarcoma; PLT, platelet.